AUM and trading activity drives Oppenheimer's wealth management business. Read why we remain bullish on OPY stock.
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...
Alphabet (GOOGL) will be stepping up to the earnings plate tomorrow (February 4), when it will deliver its fourth quarter ...
Hosted on MSN20h
Oppenheimer’s Worst Fear…Over the years, we’ve heard hundreds of time about how we have enough nuclear weapons to destroy the world. But is that ...
About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...
After the music industry gave out its prestigious Grammys Sunday, the film community is gearing up for its ceremony to take ...
This year’s Doomsday Clock Statement landed like a damp squib in a Trump-swamped corporate news cycle on January 28th. The ...
Patient Capital Management stated the following regarding Coinbase Global, Inc. (NASDAQ:COIN) in its Q4 2024 investor letter: ...
1don MSN
Last year’s Oscar winners Emma Stone, Cillian Murphy, Da’Vine Joy Randolph and Robert Downey Jr. are set to return to the ...
Albemarle (NYSE:ALB – Get Free Report) was downgraded by research analysts at Evercore ISI from an “outperform” rating to an ...
LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...
Oppenheimer (NYSE:OPY – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Oppenheimer Trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results